Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit.
This is according to a new breakdown from Medidata, now owned by Dassault Systèmes, which aims to show by numbers how the COVID-19 pandemic has impacted global clinical trials.
The firm’s analysis of data from 4,599 studies and 182,321 study-sites shows a stark retreat: The year-on-year difference between March 2019 and March 2020 across all reported countries and targeted disease areas saw trial enrollment down around 65% on average.
